Table 2.
Absolute risk in percent and adjusted hazard ratios (HRs) with 95% confidence intervals (CI) of thromboembolic and bleeding complications in patients with atrial fibrillation during the first year after a prescription for a vitamin K antagonist or a non‐vitamin K antagonist oral anticoagulant in patients with and without cancer, Denmark, July 2004 through December 2013
| Vitamin K antagonist | No cancer | Cancer | HR (95% CI)a | HR (95% CI)b | ||
|---|---|---|---|---|---|---|
| Events, n | Risk (95% CI) | Events, n | Risk (95% CI) | |||
| Thromboembolic complicationsc | 2734 | 5.8 (5.6, 6.0) | 628 | 6.5 (6.0, 7.0) | 1.0 (0.93, 1.1) | 1.1 (0.91, 1.2) |
| Ischemic stroke | 1426 | 3.1 (3.0 3.3) | 302 | 3.4 (3.0, 3.7) | 0.92 (0.81, 1.1) | 0.92 (0.73, 1.2) |
| Venous thromboembolism | 527 | 1.1 (1.0, 1.2) | 162 | 1.7 (1.5, 2.0) | 1.4 (1.2, 1.7) | 1.7 (1.2, 2.5) |
| Arterial embolism | 70 | 0.15 (0.12, 0.19) | 18 | 0.19 (0.12, 0.30) | 1.1 (0.66, 1.9) | 1.2 (0.53, 2.9) |
| Myocardial infarction | 739 | 1.6 (1.5, 1.7) | 154 | 1.6 (1.4, 1.9) | 0.93 (0.78, 1.1) | 1.0 (0.75, 1.3) |
| Bleeding complicationsc | 2025 | 4.2 (4.1, 4.5) | 513 | 5.4 (4.9, 5.8) | 1.1 (1.0, 1.2) | 1.2 (1.0, 1.3) |
| Hemorrhagic stroke | 229 | 0.49 (0.43, 0.56) | 52 | 0.54 (0.41, 0.71) | 0.94 (0.70, 1.3) | 1.2 (0.83, 1.8) |
| Gastrointestinal hemorrhage | 690 | 1.5 (1.4, 1.6) | 184 | 1.9 (1.7, 2.2) | 1.1 (0.95, 1.3) | 1.2 (0.94, 1.5) |
| Lung and urinary hemorrhage | 1111 | 2.4 (2.3, 2.5) | 277 | 2.9 (2.6, 3.2) | 1.2 (1.0, 1.3) | 1.1 (0.92, 1.4) |
| Non‐vitamin K antagonist oral anticoagulant | ||||||
| Thromboembolic complicationsc | 290 | 5.1 (4.5, 5.7) | 65 | 4.9 (3.8, 6.2) | 0.80 (0.61, 1.1) | 1.2 (0.78, 1.9) |
| Ischemic stroke | 188 | 3.4 (3.0, 4.0) | 40 | 3.0 (2.2, 4.1) | 0.77 (0.55, 1.1) | 1.2 (0.67, 2.2) |
| Venous thromboembolism | 30 | 0.53 (0.36, 0.75) | 12 | 0.98 (0.53, 1.7) | 1.4 (0.72, 2.8) | 3.9 (1.3, 11) |
| Arterial embolism | 8 | 0.17 (0.08, 0.33) | 0 | N/A | N/A | N/A |
| Acute myocardial infarction | 65 | 1.2 (0.91, 1.5) | 13 | 1.1 (0.61, 1.8) | 0.72 (0.39, 1.3) | 0.73 (0.25, 2.2) |
| Bleeding complicationsc | 166 | 3.1 (2.6, 3.6) | 60 | 4.4 (3.4, 5.6) | 1.2 (0.92, 1.7) | 1.2 (0.74, 1.8) |
| Hemorrhagic stroke | 10 | 0.21 (0.11, 0.39) | 6 | 0.56 (0.23, 1.2) | 2.2 (0.77, 6.1) | 2.5 (0.78, 7.8) |
| Gastrointestinal hemorrhage | 53 | 0.92 (0.70, 1.2) | 27 | 1.8 (1.2, 2.6) | 1.7 (1.0, 2.7) | 1.5 (0.77, 3.0) |
| Lung and urinary hemorrhage | 103 | 2.0 (1.6, 2.4) | 27 | 2.0 (1.4, 2.9) | 0.92 (0.60, 1.4) | 0.75 (0.38, 1.5) |
N/A indicates no cases.
Hazard ratios comparing thromboembolic and bleeding complications and death in atrial fibrillation patients with cancer versus without cancer.
Excludes patients (n = 23,206) with prevalent thromboembolic or bleeding events.
Events were not mutually exclusive. The number of specific events therefore does not necessarily add up to the total number of events.